SOO-rah-min
A century-old antiparasitic drug being re-explored for its ability to modulate purinergic signaling — a pathway linked to autism and immune function.
Also known as: Germanin
Last reviewed: April 2026
Suramin was developed in 1916 for African sleeping sickness. Recent research has discovered it blocks purinergic receptors (P2X and P2Y) — part of the 'cell danger response.' This has generated interest in autism spectrum disorder (ASD) research, where a small trial showed temporary symptom improvement, and in immune/mitochondrial function.
IV infusion in clinical setting only
Frequency
Single doses or short courses
Pain Level
●○○ Minimal
Self-Administered
Clinic only
Typical Range
20mg/kg (research dosing)
Hours to days
Purinergic modulation effects begin.
Weeks
Effects persist due to long half-life.
Overall: Moderate to Serious
Adrenal effects
Can affect adrenal function.
Call your doctor if you experience this.
Kidney toxicity
Nephrotoxic at higher doses. Monitor kidney function.
Call your doctor if you experience this.
Neuropathy
Peripheral nerve effects possible.
Call your doctor if you experience this.
• Kidney disease
• Adrenal insufficiency
• Pregnancy
• Requires medical supervision — IV only
• Nephrotoxic drugs — additive kidney risk
• This is a serious medication requiring close monitoring
Pregnancy: Absolutely contraindicated in pregnancy.
This compound is in early research stages. We do not currently offer it.
Looking for something similar? See what we offer for Immune.
This compound is in early research stages. It has not been FDA-approved and may not be available through compounding pharmacies. The information below is for educational purposes only. Do not attempt to self-administer research compounds.